BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 17461736)

  • 1. New treatments for acute humoral rejection of kidney allografts.
    Venetz JP; Pascual M
    Expert Opin Investig Drugs; 2007 May; 16(5):625-33. PubMed ID: 17461736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation.
    Ibernón M; Gil-Vernet S; Carrera M; Serón D; Moreso F; Bestard O; Cruzado JM; Grinyó JM
    Transplant Proc; 2005 Nov; 37(9):3743-5. PubMed ID: 16386524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early and late humoral rejection: a clinicopathologic entity in two times.
    Péfaur J; Díaz P; Panace R; Salinas P; Fiabane A; Quinteros N; Chea R; Naranjo E; Wurgaft A; Beltran E; Elgueta S; Wegmann ME; Gajardo JG; Contreras L
    Transplant Proc; 2008 Nov; 40(9):3229-36. PubMed ID: 19010241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-mediated rejection and treatment in pediatric patients: one center's experience.
    Gulleroglu K; Baskin E; Bayrakci US; Turan M; Ozdemir BH; Moray G; Karakayali H; Haberal M
    Exp Clin Transplant; 2013 Oct; 11(5):404-7. PubMed ID: 24128133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of C4d-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin.
    Shah A; Nadasdy T; Arend L; Brennan J; Leong N; Coppage M; Orloff M; Demme R; Zand MS
    Transplantation; 2004 May; 77(9):1399-405. PubMed ID: 15167598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of acute antidonor antibody-mediated humoral rejection after renal transplantation with specific consideration of serial graft biopsy histology.
    Shimizu T; Tokiwa M; Yamaguchi Y
    Clin Transplant; 2002; 16 Suppl 8():62-7. PubMed ID: 12464135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasmapheresis in C4d-positive acute humoral rejection following kidney transplantation: a review of 4 cases.
    Lennertz A; Fertmann J; Thomae R; Illner WD; Hillebrand GE; Feucht HE; Land W; Samtleben W; Bosch T
    Ther Apher Dial; 2003 Dec; 7(6):529-35. PubMed ID: 15018239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection.
    Theruvath TP; Saidman SL; Mauiyyedi S; Delmonico FL; Williams WW; Tolkoff-Rubin N; Collins AB; Colvin RB; Cosimi AB; Pascual M
    Transplantation; 2001 Jul; 72(1):77-83. PubMed ID: 11468538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Induction treatment by combining immunoglobulins, plasmapheresis and rituximab in hypersensitive patients receiving cadaveric renal allograft].
    Rufino Hernández JM; Cabello Moya E; González-Posada JM; Hernández Marrero D; Pérez Tamajón L; Marrero Miranda D; García Rebollo S; Martín Urcuyo B; Rodríguez Hernández A; Franco Maside A; Barrios del Pino Y; Rodríguez Rodríguez R; Maceira Cruz B; Torres Ramírez A; Salido Ruiz E
    Nefrologia; 2010; 30(2):252-7. PubMed ID: 20098463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late acute antibody mediated rejection after nine years of renal transplantation.
    Halim MA; Al-Otaibi T; Al-Waheeb S; Tawab KA; El Kholy O; Nair P; Said T; Narayanan Nampoory MR
    Saudi J Kidney Dis Transpl; 2010 Nov; 21(6):1111-4. PubMed ID: 21060182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pinpoint targeted immunosuppression: anti-CD20/MMF desensitization with anti-CD25 in successful ABO-incompatible kidney transplantation without splenectomy.
    Saito K; Nakagawa Y; Suwa M; Kumagai N; Tanikawa T; Nishiyama T; Ueno M; Gejyo F; Nishi S; Takahashi K
    Xenotransplantation; 2006 Mar; 13(2):111-7. PubMed ID: 16623803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis.
    Sawada T; Fuchinoue S; Teraoka S
    Transplantation; 2002 Nov; 74(9):1207-10. PubMed ID: 12451255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes of ABO-incompatible kidney transplant with rituximab and double-filtration plasmapheresis.
    Han S; Hwang E; Park S; Park U; Kim H; Cho W
    Exp Clin Transplant; 2014 Oct; 12(5):401-4. PubMed ID: 25299367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection.
    Fehr T; Rüsi B; Fischer A; Hopfer H; Wüthrich RP; Gaspert A
    Transplantation; 2009 Jun; 87(12):1837-41. PubMed ID: 19543061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients.
    Montgomery RA; Zachary AA; Racusen LC; Leffell MS; King KE; Burdick J; Maley WR; Ratner LE
    Transplantation; 2000 Sep; 70(6):887-95. PubMed ID: 11014642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics.
    Crespo M; Pascual M; Tolkoff-Rubin N; Mauiyyedi S; Collins AB; Fitzpatrick D; Farrell ML; Williams WW; Delmonico FL; Cosimi AB; Colvin RB; Saidman SL
    Transplantation; 2001 Mar; 71(5):652-8. PubMed ID: 11292296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Role of antibodies in kidney transplant].
    Ruffoni E; Seveso M; Marson P; Tison T; Cozzi E
    G Ital Nefrol; 2012; 29 Suppl 54():S54-60. PubMed ID: 22388831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of high-dose mizoribine in ABO-incompatible kidney transplantation using anti-CD20 and anti-CD25 antibody without splenectomy treatment.
    Yoshimura N; Ushigome H; Matsuyama M; Nobori S; Suzuki T; Sakai K; Okajima H; Okamoto M
    Transplant Proc; 2012 Jan; 44(1):140-3. PubMed ID: 22310599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress in understanding humoral rejection in kidney transplantation: implications for patient management.
    Pascual MA; Crespo M; Tolkoff-Rubin N
    Nefrologia; 2001; 21(4):327-31. PubMed ID: 11816504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.